-
公开(公告)号：WO2023064446A1
公开(公告)日：2023-04-20
申请号：PCT/US2022/046535
申请日：2022-10-13
Applicant: PACIRA PHARMACEUTICALS, INC.
Inventor： DAVIS, Paige, N. , ARDEKANI, Soroush, M. , KURZ, Stephanie, M. , GARCIA, Louie, D. , LOS, Kathleen, D.A. , GRIGSBY, John, J., Jr. , LEON, Damon A. , LEVY, Eran , SIMONIAN, Alisha R.
Abstract: Some embodiments of the present application are related to multivesicular liposome (MVL) formulations encapsulating dexamethasone or an ester or an ester salt thereof, for example, dexamethasone sodium phosphate (DSP) that may provide about 3-28 days extended release of dexamethasone. Processes of making and administering dexamethasone encapsulated multivesicular liposome formulations and their uses for treating pain or inflammation are also provided.
-
公开(公告)号：WO2023063567A1
公开(公告)日：2023-04-20
申请号：PCT/KR2022/012796
申请日：2022-08-26
Applicant: 사회복지법인 삼성생명공익재단 , 성균관대학교 산학협력단
Abstract: 본 발명은 브루세안틴(Bruceantin) 및 나노입자를 포함하는 거세 저항성 전립선암 치료용 약학적 조성물에 관한 것이다. 일 구체예에 따른 브루세안틴 및 나노입자를 포함하는 조성물을 이용하면 브루세안틴의 부작용이 감소하고 난용성이 개선되어 거세 저항성 전립선암을 효과적으로 치료할 수 있다.
-
公开(公告)号：WO2023049302A1
公开(公告)日：2023-03-30
申请号：PCT/US2022/044457
申请日：2022-09-22
Applicant: PROCAPS SA
Inventor： GUTIERREZ, Wilson, Martinez , PADILLA, Alvaro, Jose Garcia , SIMANCA, Alfredo, de Jesús Puche , BUSTILLO, Tatiana, Lucia Yepes
IPC: A61K9/48 , A61K31/23 , A61K31/685 , A61K47/14 , A61K47/24 , A23L33/115 , C12P7/6481
Abstract: The invention provides a process of incorporation of omega- 3 fatty acids such as EPA/DHA into polar lipid molecules present in lecithin, which consists of: (a) an enzymatic exchange reaction between the fatty acids present in the polar lipids of lecithin and the omega-3 fatty acids present in concentrated fish oil, to obtain an oil with a high content of polar lipids and omega-3 fatty acids and (b) a stage of concentration of the polar lipid content of the oil obtained in stage a, by supercritical fractionation or molecular distillation.
-
公开(公告)号：WO2023040879A1
公开(公告)日：2023-03-23
申请号：PCT/CN2022/118658
申请日：2022-09-14
Applicant: COVAL BIOPHARMA (SHANGHAI) CO., LTD.
Inventor： WU, Guolong , ZHANG, Weijiang , FENG, Lichun , ZHANG, Hao , LI, Dafeng
Abstract: Disclosed herein are drug delivery systems and methods for locally delivering therapeutic agents, and methods for using such drug delivery systems for the treatment of diseases.
-
公开(公告)号：WO2023027032A1
公开(公告)日：2023-03-02
申请号：PCT/JP2022/031584
申请日：2022-08-22
Applicant: 住友ファーマ株式会社
IPC: C07D405/14 , A61K9/127 , A61K31/4545 , A61K31/5377 , A61K45/00 , A61K47/24 , A61K47/28 , A61K47/32 , A61K47/34 , A61P35/00 , A61P35/02 , A61P43/00 , C07D413/14
Abstract: 自己分解型ＣＤＫ９阻害剤プロドラッグ及びそれを内封するリポソームを提供する。式（１）で表される化合物又はその製薬学的に許容される塩 ［式中、Ｒ１は、置換されていてもよいＣ１－６アルキル基であり、Ｒ２及びＲ３は、同一又は異なって、各々独立して、水素原子、又は置換されていてもよいＣ１－６アルキル基であり、Ｘは、ＣＨ２又は酸素原子であり、ｎは、１又は２であり、ｐは、０、１又は２であり、ｑは、１又は２であり、ｒは、０、１又は２であり、ここにおいて、Ｘが酸素原子であるとき、ｑは２である。］。
-
Patent Agency Ranking
公开(公告)号：WO2023025272A1
公开(公告)日：2023-03-02
申请号：PCT/CN2022/115027
申请日：2022-08-26
Applicant: 南京清普生物科技有限公司
Abstract: 本发明涉及一种药物组合物，包含药学上的活性成分、甘油、缓释载体和药学上可接受的溶剂。所述药物组合物刺激性小，具有良好的缓释性能，用药安全性及耐受性，且在常温下为高粘度液体，特别有利于灌注给药。
-
公开(公告)号：WO2023019310A1
公开(公告)日：2023-02-23
申请号：PCT/AU2022/050913
申请日：2022-08-17
Applicant: MONASH UNIVERSITY
Inventor： AL-WASSITI, Hareth Basim Ali , POUTON, Colin William , HO, Kha Tu Joan
IPC: A61K39/00 , A61K31/105 , A61K47/18 , A61K47/24 , A61K47/28 , A61K47/34 , A61K9/00 , A61K9/51 , A61P29/00 , A61P37/06 , A61P37/08
Abstract: The present invention is directed to lipid nanoparticles, formulations containing lipid nanoparticles and methods of treating diseases or conditions with said lipid nanoparticles and formulations thereof. A lipid nanoparticle comprising (a) an active agent; (b) a cationic and/or ionisable lipid comprising from about 40 mol % to about 60 mol % of the total lipid present in the nanoparticle; (c) a phospholipid comprising from about 5 mol % to about 20 mol % of the total lipid present in the nanoparticle; (d) a structural lipid comprising from about 30 mol % to about 50 mol % of the total lipid present in the nanoparticle; (e) a PEGylated lipid comprising from about 0.05 mol % to less than 0.5 mol % of the total lipid present in the nanoparticle.
-
公开(公告)号：WO2023017925A1
公开(公告)日：2023-02-16
申请号：PCT/KR2021/020297
申请日：2021-12-30
Applicant: 단국대학교 산학협력단
Inventor： 김규오
Abstract: 본 발명은 글루코스의 농도, pH, 온도 또는 파장 등의 외부 자극에 의해 자가 조절되는, 아미노페닐보론산(APBA)으로 기능화된 다면체 올리고머릭 실세스퀴옥산(POSS) 및 인슐린을 포함하는 인슐린 약물 전달체에 관한 것으로서, 본 발명에 따른 인슐린 약물 전달체는 바이오센서 또는 혈당 체크의 어려움 및 불편함이 없이 약물 방출을 쉽게 조절할 수 있다는 장점이 있다.
-
公开(公告)号：WO2022268882A1
公开(公告)日：2022-12-29
申请号：PCT/EP2022/067018
申请日：2022-06-22
Applicant: ALTERGON S.A.
Inventor： PUPPINI, Nadia , NICOLINI, Valentina , FOSSATI, Tiziano
IPC: A61K9/06 , A61K47/24 , A61K31/196 , A61P19/02 , A61P29/00 , A61K9/0014
Abstract: Pharmaceutical compositions for topical use comprising diclofenac in the form of salt with epolamine, present at concentrations higher than 2.0% by weight are described. Such compositions provide, with respect to those currently available, a more complete absorption of the administered dose, reducing the dispersion of active ingredient and allowing to carry out treatments requiring the administration of high and accurate dosages.
-
公开(公告)号：WO2022244844A1
公开(公告)日：2022-11-24
申请号：PCT/JP2022/020849
申请日：2022-05-19
Applicant: 国立大学法人北海道大学
IPC: A61K47/16 , A61K9/10 , A61K9/127 , A61K31/7105 , A61K31/713 , A61K47/02 , A61K47/24 , A61K47/28 , A61K47/44 , A61K48/00 , A61P35/00 , A61P37/04
Abstract: 本発明は、ｐＨ感受性カチオン性脂質とポリアルキレングリコール修飾脂質とを含有しており、脂質ナノ粒子を構成する全脂質量に対する、前記ｐＨ感受性カチオン性脂質の含有量の割合が１０～２５モル％であり、脂質ナノ粒子を構成する全脂質量に対する、前記ポリアルキレングリコール修飾脂質の含有量の割合が０．５～１．７５モル％であり、個数平均粒子径が１５０ｎｍ以上である、脂質ナノ粒子等を提供する。
-
-
-
-
-
-
-
-
-
Search Results
1798
records
(took 0.075 seconds)
